New drug combo shows promise in early brain cancer trial
NCT ID NCT06095375
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 21 times
Summary
This early-stage study tested adding the drug regorafenib to standard chemotherapy and radiation for people with a specific type of aggressive brain cancer (glioblastoma). The goal was to find a safe dose and see if the combination is tolerable. 21 adults with newly diagnosed, MGMT-methylated glioblastoma took part. The study focused on side effects and finding the right dose, not yet on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Humanitas Research Hospital
Rozzano, 20089, Italy
-
Istituto Oncologico Veneto IRCCS
Padova, 35128, Italy
Conditions
Explore the condition pages connected to this study.